When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?

J Clin Oncol. 2017 May 1;35(13):1487-1488. doi: 10.1200/JCO.2016.71.0103. Epub 2017 Jan 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers
  • Everolimus
  • Humans
  • Neuroendocrine Tumors*
  • Pancreatic Neoplasms*

Substances

  • Biomarkers
  • Everolimus